Premium
Prognostic value of cystatin C in patients with acute coronary syndrome: A systematic review and meta‐analysis
Author(s) -
Sun Ying,
Lu Qing,
Cheng Biao,
Tao Xuefei
Publication year - 2021
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.13440
Subject(s) - mace , cystatin c , medicine , hazard ratio , acute coronary syndrome , myocardial infarction , meta analysis , cochrane library , population , cardiology , confidence interval , creatinine , percutaneous coronary intervention , environmental health
Background Circulating cystatin C has been considered as an independent predictor of cardiovascular and all‐cause mortality in the general population. The purpose of this study was to evaluate the prognostic value of baseline circulating cystatin C levels in patients with acute coronary syndrome (ACS) through meta‐analysis. Methods Prospective studies about the relationship between the level of cystatin C and the prognosis of ACS patients were searched on PubMed, Web of science, Cochrane Library and Embase databases from the establishment of the databases to July 2020. The prognostic values included in this analysis covered all‐cause mortality, major adverse cardiovascular events (MACE) and recurrent myocardial infarction. The effect index between cystatin C level and ACS risk was carried out by hazard ratio (HR). Stata 15.0 software was used for statistical analysis. The quality of the included literature was evaluated according to Newcastle‐Ottawa Scale (NOS). Results A total of 10 studies were included in this meta‐analysis. The results showed that high cystatin C levels significantly predicted the all‐cause mortality of ACS, HR = 2.53 (95%CI: 1.72 ~ 3.72). High cystatin C level significantly predicted MACE of patients with ACS, HR = 3.24 (95%CI: 1.30 ~ 8.07). However, it had no significant predictive significance for recurrent myocardial infarction, HR = 1.71 (95%CI:0.99 ~ 2.97). Conclusion Our meta‐analysis showed that high cystatin C levels were significantly associated with the death risk and MACE in ACS patients. Therefore, cystatin C can be included in the risk stratification model to guide the treatment of high‐risk ACS patients.